| Drug General Information |
| Drug ID |
D0O2XJ
|
| Former ID |
DIB013496
|
| Drug Name |
NXN-188
|
| Synonyms |
Acute migraine therapy, NeurAxon; NXN-188 (oral); NXN-188 (oral), NeurAxon
|
| Drug Type |
Small molecular drug
|
| Indication |
Migraine [ICD9: 346; ICD10:G43]
|
Phase 2 |
[1]
|
|---|
| Company |
Neuraxon
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C27H36N8O5
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 1B receptor |
Target Info |
Modulator |
|
|---|
| 5-hydroxytryptamine 1D receptor |
Target Info |
Modulator |
|
|
KEGG Pathway
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04024:cAMP signaling pathway
|
|
Serotonergic synapse
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Serotonin HTR1 Group and FOS Pathway
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
|
|
GPCR downstream signaling
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00920686) Study of NXN 188 for the Treatment of Migraine With Aura. U.S. National Institutes of Health. |
|---|
